CN1193894A - 两阶段制剂 - Google Patents
两阶段制剂 Download PDFInfo
- Publication number
- CN1193894A CN1193894A CN96196562A CN96196562A CN1193894A CN 1193894 A CN1193894 A CN 1193894A CN 96196562 A CN96196562 A CN 96196562A CN 96196562 A CN96196562 A CN 96196562A CN 1193894 A CN1193894 A CN 1193894A
- Authority
- CN
- China
- Prior art keywords
- product
- amount
- weight
- amino acid
- stage preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 61
- 239000000047 product Substances 0.000 claims abstract description 116
- 150000001413 amino acids Chemical class 0.000 claims abstract description 37
- 229940088594 vitamin Drugs 0.000 claims abstract description 32
- 229930003231 vitamin Natural products 0.000 claims abstract description 32
- 235000013343 vitamin Nutrition 0.000 claims abstract description 32
- 239000011782 vitamin Substances 0.000 claims abstract description 32
- 239000011573 trace mineral Substances 0.000 claims abstract description 30
- 235000013619 trace mineral Nutrition 0.000 claims abstract description 30
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 26
- 239000000203 mixture Substances 0.000 claims abstract description 24
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 9
- 229940024606 amino acid Drugs 0.000 claims description 36
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 30
- 241000196324 Embryophyta Species 0.000 claims description 25
- 239000011701 zinc Substances 0.000 claims description 19
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 17
- 239000011149 active material Substances 0.000 claims description 17
- 239000011777 magnesium Substances 0.000 claims description 17
- 229910052749 magnesium Inorganic materials 0.000 claims description 17
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 15
- 235000010755 mineral Nutrition 0.000 claims description 15
- 239000011707 mineral Substances 0.000 claims description 15
- 229910052725 zinc Inorganic materials 0.000 claims description 14
- 235000016804 zinc Nutrition 0.000 claims description 14
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 12
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 10
- 239000011575 calcium Substances 0.000 claims description 10
- 229910052791 calcium Inorganic materials 0.000 claims description 10
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 claims description 9
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 8
- 235000020971 citrus fruits Nutrition 0.000 claims description 8
- 229940083466 soybean lecithin Drugs 0.000 claims description 8
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 6
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 6
- 239000011651 chromium Substances 0.000 claims description 6
- 229910052804 chromium Inorganic materials 0.000 claims description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- 229960003512 nicotinic acid Drugs 0.000 claims description 6
- 239000011664 nicotinic acid Substances 0.000 claims description 6
- 235000001968 nicotinic acid Nutrition 0.000 claims description 6
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- 229910052710 silicon Inorganic materials 0.000 claims description 5
- 239000010703 silicon Substances 0.000 claims description 5
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 claims description 4
- 235000017647 Brassica oleracea var italica Nutrition 0.000 claims description 4
- 240000003259 Brassica oleracea var. botrytis Species 0.000 claims description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 4
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 3
- 241000207199 Citrus Species 0.000 claims description 3
- 244000000626 Daucus carota Species 0.000 claims description 3
- 235000002767 Daucus carota Nutrition 0.000 claims description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
- 244000269722 Thea sinensis Species 0.000 claims description 3
- 229930003451 Vitamin B1 Natural products 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- 235000009569 green tea Nutrition 0.000 claims description 3
- 229940055726 pantothenic acid Drugs 0.000 claims description 3
- 235000019161 pantothenic acid Nutrition 0.000 claims description 3
- 239000011713 pantothenic acid Substances 0.000 claims description 3
- 229960003495 thiamine Drugs 0.000 claims description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical group Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 3
- 235000010374 vitamin B1 Nutrition 0.000 claims description 3
- 239000011691 vitamin B1 Substances 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- 239000010775 animal oil Substances 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 229960004203 carnitine Drugs 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 229960003104 ornithine Drugs 0.000 claims description 2
- 229960003080 taurine Drugs 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims 1
- 239000010773 plant oil Substances 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 12
- 235000013325 dietary fiber Nutrition 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 3
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 abstract 1
- 150000003862 amino acid derivatives Chemical class 0.000 abstract 1
- 230000000975 bioactive effect Effects 0.000 abstract 1
- 229940093797 bioflavonoids Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 125000004402 polyphenol group Chemical group 0.000 abstract 1
- 239000008347 soybean phospholipid Substances 0.000 abstract 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 abstract 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 abstract 1
- 239000002775 capsule Substances 0.000 description 27
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 18
- 235000001055 magnesium Nutrition 0.000 description 16
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 15
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 13
- 230000003203 everyday effect Effects 0.000 description 11
- 235000015097 nutrients Nutrition 0.000 description 11
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000004060 metabolic process Effects 0.000 description 10
- 235000016709 nutrition Nutrition 0.000 description 10
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 10
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 9
- 229930003268 Vitamin C Natural products 0.000 description 9
- 229930003935 flavonoid Natural products 0.000 description 9
- 150000002215 flavonoids Chemical class 0.000 description 9
- 235000017173 flavonoids Nutrition 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 230000035764 nutrition Effects 0.000 description 9
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 9
- 235000019154 vitamin C Nutrition 0.000 description 9
- 239000011718 vitamin C Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 230000036541 health Effects 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 229930003427 Vitamin E Natural products 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 6
- 235000021388 linseed oil Nutrition 0.000 description 6
- 239000000944 linseed oil Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 235000019165 vitamin E Nutrition 0.000 description 6
- 239000011709 vitamin E Substances 0.000 description 6
- 241000167854 Bourreria succulenta Species 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 235000019693 cherries Nutrition 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 229910052742 iron Inorganic materials 0.000 description 5
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 5
- 239000007901 soft capsule Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 235000019158 vitamin B6 Nutrition 0.000 description 5
- 239000011726 vitamin B6 Substances 0.000 description 5
- 229940011671 vitamin b6 Drugs 0.000 description 5
- DTOSIQBPPRVQHS-PDBXOOCHSA-N (Z,Z,Z)-Octadeca-9,12,15-trienoic acid Natural products CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 description 4
- 235000013824 polyphenols Nutrition 0.000 description 4
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- 229930003471 Vitamin B2 Natural products 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 229940023136 pantothenic acid 10 mg Drugs 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 102000037983 regulatory factors Human genes 0.000 description 3
- 108091008025 regulatory factors Proteins 0.000 description 3
- 229960002477 riboflavin Drugs 0.000 description 3
- 235000019156 vitamin B Nutrition 0.000 description 3
- 239000011720 vitamin B Substances 0.000 description 3
- 235000019164 vitamin B2 Nutrition 0.000 description 3
- 239000011716 vitamin B2 Substances 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000010497 wheat germ oil Substances 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- RVSTWRHIGKXTLG-UHFFFAOYSA-N Pangamic acid Natural products CC(C)N(C(C)C)C(N(C(C)C)C(C)C)C(=O)OCC(O)C(O)C(O)C(O)C(O)=O RVSTWRHIGKXTLG-UHFFFAOYSA-N 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- ASARMUCNOOHMLO-WLORSUFZSA-L cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2s)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O ASARMUCNOOHMLO-WLORSUFZSA-L 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 235000020774 essential nutrients Nutrition 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 2
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 2
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 2
- 229960002733 gamolenic acid Drugs 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 229940055705 pangamic acid Drugs 0.000 description 2
- ZQTHOIGMSJMBLM-BUJSFMDZSA-N pangamic acid Chemical compound CN(C)CC(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O ZQTHOIGMSJMBLM-BUJSFMDZSA-N 0.000 description 2
- 108700024047 pangamic acid Proteins 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- HGUVPEBGCAVWID-KETMJRJWSA-N 7-O-(beta-D-glucosyl)isovitexin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1O)[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 HGUVPEBGCAVWID-KETMJRJWSA-N 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- SJEYSFABYSGQBG-UHFFFAOYSA-M Patent blue Chemical compound [Na+].C1=CC(N(CC)CC)=CC=C1C(C=1C(=CC(=CC=1)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=CC(=[N+](CC)CC)C=C1 SJEYSFABYSGQBG-UHFFFAOYSA-M 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940093740 amino acid and derivative Drugs 0.000 description 1
- 230000001399 anti-metabolic effect Effects 0.000 description 1
- 230000002460 anti-migrenic effect Effects 0.000 description 1
- 230000003167 anti-vitamin Effects 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 235000002201 avitaminosis Nutrition 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 229940008396 carrot extract Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940010007 cobalamins Drugs 0.000 description 1
- 150000001867 cobalamins Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004232 linoleic acid Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000019488 nut oil Nutrition 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- IZMJMCDDWKSTTK-UHFFFAOYSA-N quinoline yellow Chemical compound C1=CC=CC2=NC(C3C(C4=CC=CC=C4C3=O)=O)=CC=C21 IZMJMCDDWKSTTK-UHFFFAOYSA-N 0.000 description 1
- 239000004172 quinoline yellow Substances 0.000 description 1
- 229940051201 quinoline yellow Drugs 0.000 description 1
- 235000012752 quinoline yellow Nutrition 0.000 description 1
- HGUVPEBGCAVWID-UHFFFAOYSA-N saponarin Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)C2C(C(O)C(O)C(CO)O2)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 HGUVPEBGCAVWID-UHFFFAOYSA-N 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- -1 vitamin A Chemical class 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nonmetallic Welding Materials (AREA)
- Medicinal Preparation (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Developing Agents For Electrophotography (AREA)
- Stereo-Broadcasting Methods (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Powder Metallurgy (AREA)
Abstract
本发明涉及在差别时间使用的两阶段制剂,其包括用于第一阶段的产物A和用于第二阶段的产物B,它们彼此独立地含有至少一种典型的不饱和脂肪酸和/或至少一种典型的微量元素和矿物质和/或至少一种典型的维生素和/或至少一种典型的植物生物活性材料,例如多酚类、生物类黄酮或膳食纤维,和/或至少一种氨基酸和/或氨基酸衍生物,产物A和/或产物B还可选择性地含有大豆卵磷脂,其前提是产物A和产物B在其数量上和/或其原料组合物上彼此不同。该制剂可用作食品补充剂(膳食补充剂)或用作药物。
Description
本发明涉及在差别时间使用的两阶段制剂，其包括用于第一阶段的产物A和用于第二阶段的产物B，它们彼此独立地含有至少一种典型的不饱和脂肪酸和/或至少一种典型的微量元素和矿物质和/或至少一种典型的维生素和/或至少一种典型的植物生物活性物质，例如多酚类、生物类黄酮或膳食纤维，和/或至少一种氨基酸和/或氨基酸衍生物，产物A和/或产物B还可选择性地含有大豆卵磷脂，其前提条件是产物A和产物B在其数量和/或其原料组合物上彼此不同。该制剂可用作食品补充剂(膳食补充剂)或用作药物。
具体地说，本发明涉及在差别时间使用的两阶段制剂，其含有产物A和产物B，它们彼此独立地包括至少一种典型的不饱和脂肪酸、一种典型的微量元素和矿物质和一种典型的维生素，产物A和/或产物B还可选择性地含有大豆卵磷脂，和/或至少一种典型的植物生物活性物质和/或至少一种氨基酸和/或氨基酸衍生物，其可用作食品补充剂(膳食补充剂)。
人们通常知道营养碳水化合物以及食物脂肪主要用来满足体能的需要。蛋白质是细胞和内源活性物质如酶和某些激素的重要构筑元件。多不饱和脂肪酸、维生素、矿物质和微量元素以及植物生物活性物质如类黄酮对于卫生和健康越来越重要。
维生素、矿物质和微量元素、多不饱和脂肪酸和植物生物活性物质如类黄酮是代谢中重要的调节因子和维护健康的营养素。但是，单一的饮食、严格的减肥食品、低营养高卡路里食品的选择、以及许多食品的高度加工、但还有就重要矿物质来说土质的部分缺乏使得很难最佳提供所有必需营养素。另外，由于有害环境的影响，抽烟、嗜酒和吃药以及紧张，某些必需营养素的需求增加了，例如镁、锌、维生素E、维生素C、B型维生素和β胡萝卜素。从而食品补充营养代替品，象高度粗糙的和低脂肪的平衡良好的营养食品那样，有助于充分提供营养素，最佳地维护身体和健康。参考资料“Empfehlungen fürdie Nhrstoffzufuhr”[供给营养的推荐值]，Deutsche Gesellschaft für Ernhrung，1991年第5版，Umschau Verlag，Frankfurt/Main，记述了向身体提供营养素的推荐值。
维生素是重要的营养成分，其对于异养生物的正常身体功能或多或少是必不可少的，其由于需要而被供给，因为它们仅能从外源获得或在外界因素(如肠内菌群)的影响下获得。它们特异的生物催化作用是代替用于代谢消耗的酶的活性成分。从科学角度我们知道例如B型维生素作为辅酶参与中间代谢，而维生素C、E和β胡萝卜素主要起抗氧剂的作用。由于不能充分提供或再吸收引起的缺乏，肠内菌群或代谢异常、抗维生素的作用或消耗的增加导致了维生素缺少症(hypovitamiuosis)和维生素缺乏病(avitaminosis)。
另外，矿物质和微量元素是代谢中的重要调节因子。钙是骨骼和牙齿最重要的矿物质构建材料。直到30岁前充分供给钙是对老年期骨质疏松症的最好防治。之后，充分的食品钙质确保骨骼中的储存是很必要的。对妇女来说钙是通常极重要的营养素。锌、镁和B型维生素是高性能要素，其使酶活化从而完成碳水化合物、脂肪和蛋白质的代谢。硅对于皮肤、毛发、指甲的稳定和保持具有有利的影响。另外，在科学上毫无争议地，锌在身体免疫系统和皮肤代谢中起重要作用。
得自纯植物来源的多不饱和脂肪酸例如晚樱油和亚麻子油，包括亚油酸和α-及γ-亚麻酸，是生物活性调节因子例如花生烯酸和前列腺素的重要初始物质，并保证了代谢中的健康平衡。花生烯酸和前列腺素还被称作组织激素，科学家们正在深入研究它们的健康稳定作用。大家已经知道了多不饱和脂肪酸对胆固醇代谢和健康皮肤功能以及感染过程具有有利的作用。大家还知道ω-3型的多不饱和脂肪酸(二十碳五烯酸、α-亚麻酸)和ω-6(亚油酸、γ-亚麻酸)脂肪酸对偏头痛、风湿病、神经性皮炎、牛皮癣、月经前症状以及在运动过程中由于身体劳损引起的恢复过程具有有利作用。(参见A.Berg，D.Knig，H.Schlachter，J.Keul，Deutsche Zeitschrift für Sportmedizin[德国运动医学杂志]，44册(1993)，特别报道，及其中引用的文献)。
胡萝卜、花茎甘蓝和柑橘提取物是维生素和矿物质的天然来源并含有所称的植物次生物质，在科学特别分支中其还被称作植物生物活性物质，人们已经认识到了其重要性并且也正在进行实验。这些天然植物物质还包括生物类黄酮，其有效地增强了维生素C对于电阻率(power ofresistance)、血管壁和结缔组织的影响。人们还知道生物类黄酮具有抗氧剂特性，从而协同性地补充了维生素C、E和β胡萝卜素的作用。绿茶也是这些植物抗氧剂(如多酚)的很好的来源(参见B.Watzl，C.Leitzmann Bioaktive Substanzen in Lebensmitteln[食物中的生物活性物质]，Hippokrates Publishing House，Stuttgart，1995)。
氨基酸不但是构建蛋白质的部件，其还是生理上有效化合物的前体，例如5-羟色胺，生长及抑制激素。还认为它们有抗代谢特性(参见，就此而论的K.R.Geiβ，M.Hamm Handbuch Sporternhrung[运动营养手册]，Rowohlt Publishing House，1992)。
从市场上可获得大量食品补充剂，其含有单一维生素(如维生素E制剂)或它们的混合物(如多种维生素的制剂)和/或单一矿物质及微量元素(如镁或铁制剂)或它们的混合物(如多种矿物质的胶囊)，还有单独的或与维生素和矿物质混合的多不饱和脂肪酸的制剂。例如，一种制剂中可含有能满足这些营养素每日需求的多种不同的维生素和某些选择的矿物质。
另一种从市场上可获得的制剂的特征是作为满足重要营养素的特定增加需要的补充性的平衡饮食，特别是考虑到特殊目的营养，例如心脏病发作或分流手术之后，代谢的紧张状态需要调整。作为每日需要，这种称之为膳食食品的由含9个片剂或胶囊的一个袋包组成，通常吃饭时或者饭后服下袋中的内容物，但是，也可能按任何特定要求全天与膳食一起服用单独的胶囊或片剂。这种制剂的每日需求包括基本的维生素如维生素A、B1、B2、B3、B6、B12、C、E、D3、K和β胡萝卜素、微量元素如铁、锌、锰、铬、镁、硒及特定的基本脂肪酸。但是，这种膳食食品所含的维生素的量大大超过健康成年人每天允许的基本推荐量。
大多数市售食品补充剂是以胶囊或片剂的形式出现，并通常是在每天的不同时间独立服用。
迄今，食品补充剂通常用来满足由于营养缺乏引起的营养上的需求。尽管有大量的食品补充剂，但还没有提供出能充分重视科学发现的适合供给的最适宜的溶液。从科学上，人们知道与在一单一给药剂型中混合各种维生素和矿物质相反，从生理学的观点上来看这些物质的分散给药更有意义。与高剂量营养素相比，较低的单独剂量更易接受。人们还知道同时摄入在一个单一给药剂型中的矿物质和微量元素会不利地影响各种成分的再吸收。其中，镁和钙以及铁、锌和硒互相有不利影响。
在许多已知制剂中，多种成分的组合物通常没有意义，因为所有基本营养素的同时服用会降低单个成分的获取(例如，如果单一药剂的钙含量比镁含量高很多则镁不会被很好地被吸收)。并且，由于铁的强氧化性，在铁和多不饱和脂肪酸之间会发生不希望的反应。
在一个上面提到的市售制剂中，使用者必须在一顿或几顿饭中每天服用九个胶囊或片剂。但是，可接受的每日剂量应当不超过每天三次单独剂量(例如一天一至三个胶囊)。
人体代谢经过白天和黑夜两阶段。人们认为这些白天和黑夜阶段也会影响营养平衡、营养吸收和身体的需要。本发明的目的是提供一种合理组合的两阶段制剂，其中营养素的每日提供是这样分配的：按照活动性营养规律供给每天的前半部分，按照恢复性营养规律供给每天的后半部分。本发明的另一个目的是提供一种满足特定靶组织需求的两阶段制剂。该两阶段制剂可被用作膳食补充剂和/或药品。
通过提供在差别时间使用的两阶段制剂完成了本发明的一个目的，该制剂包括用于第一阶段(活动阶段)的产物A和用于第二阶段(恢复阶段)的产物B，其中产物A包括：
a)至少一种典型的不饱和脂肪酸和/或
b)至少一种典型的微量元素和矿物质和/或
c)至少一种典型的维生素和/或
d)至少一种典型的植物生物活性物质和/或
e)至少一种氨基酸和/或氨基酸衍生物
而产物B包括：
a)至少一种典型的不饱和脂肪酸和/或
b)至少一种典型的微量元素和矿物质和/或
c)至少一种典型的维生素和/或
d)至少一种典型的植物生物活性物质和/或
e)至少一种典型的氨基酸和/或氨基酸衍生物
其前提条件是产物A和产物B在它们的数量和/或原料组合物上彼此不同。
在优选的实施方案中，本发明还提供了一种在差别时间使用的两阶段制剂，该制剂包括用于第一阶段的产物A和用于第二阶段的产物B，其中产物A包括
a)至少一种典型的不饱和脂肪酸
b)至少一种典型的微量元素和矿物质及
c)至少一种典型的维生素
而产物B包括
a)至少一种典型的不饱和脂肪酸
b)至少一种典型的微量元素和矿物质及
c)至少一种典型的维生素。
在特别优选的实施方案中，提供了一种在差别时间使用的两阶段膳食补充剂，其包括用于第一阶段的产物A和用于第二阶段的产物B，其中产物A和产物B每一个彼此独立地包括
a)至少一种典型的不饱和脂肪酸
b)至少一种典型的微量元素和矿物质及
c)至少一种典型的维生素。
在另一个优选的实施方案中，产物A和/或产物B可另外包含大豆卵磷脂。优选加入的大豆卵磷脂的量是1-40％重量，最优选5-20％重量，分别地，是基于产物A和产物B所有活性成分的总和。
在进一步的实施方案中，优选实施方案中的产物A和/或产物B可另外包含至少一种典型的植物生物活性物质。
在进一步的实施方案中，优选实施方案中的产物A和/或产物B可另外包含氨基酸和/或氨基酸衍生物，也是与本发明的其它活性成分相混合。
术语“在差别时间使用”是指在白天阶段或活性阶段的开始施予产物A或达到其效果，而在人体代谢的夜晚阶段或恢复阶段的开始施予产物B或达到其效果。优选地，产物A是在早上给药而产物B是在同一天的晚上给药。
术语“两阶段”是指白天或活动阶段作为第一阶段(一天的前半部分)而晚上或恢复阶段作为人体代谢的第二阶段(一天的后半部分)。
本发明的产物A和产物B在它们的数量和/或原料组合物上彼此不同。
本发明的配方优选考虑到协同作用，例如在维生素C与生物类黄酮以及维生素C与多不饱和脂肪酸的情况下。
在本发明的两阶段制剂中，产物A和B可以包括所有已知的典型维生素。具体地说，两阶段制剂的产物A优选包含维生素C和E作为抗氧剂(细胞保护维生素)，以及维生素B1、B2、B6、B12、泛酸、β胡萝卜素和烟酸，而产物B优选包含维生素B1、B2。B6、B12、泛酸、烟酸以及叶酸和生物素作为碳水化合物、脂肪和蛋白质代谢中在辅酶意义上的代谢调节因子。
在优选的本发明的两阶段制剂的实施方案中，优选维生素的含量是产物A重量的1-70％，是产物B重量的0.5-50％，分别地，基于产物A和B的所有活性成分的总量。在更优选的实施方案中，产物A包含5-50％重量的维生素，特别优选20-45％重量，而产物B包含1-40％重量的维生素，特别优选1-35％重量。加入的维生素可以是天然提取物形式(例如D-α-生育酚)也可以是合成的形式(例如B-型维生素)，但是，这些不会影响维生素的作用效果。
本发明的两阶段制剂中的典型微量元素和矿物质包括所有已知的矿物质和微量元素。在优选的实施方案中，两阶段制剂的产物A具体包含锌、镁和铬而产物B包含硅、镁、锌和钙。在优选的实施方案中矿物质和微量元素的含量优选是产物A和产物B重量的1-80％，更优选是产物A重量的2-50％，特别优选重量的5-30％，是产物B重量的2-70％，特别优选重量的3-60％，分别地，基于产物A和B所有活性成分的总量。优选加入的微量元素是以铬、锌和硅酵母或其它有机化合物的形式。主要的元素，例如镁和钙，是以无机盐化合物或有机化合物的形式出现。例如，以碳酸镁或碳酸钙的形式加入镁或钙。
在本发明的两阶段制剂中可以使用所有已知的不饱和脂肪酸。优选地，使用植物或动物油中含有的不饱和脂肪酸。得自植物或动物来源的多不饱和脂肪酸是重要的代谢调节因子(花生烯酸和前列腺素)的基本前体。在优选的两阶段制剂的实施方案中，优选出现在产物A中的不饱和脂肪酸的量是5-90％重量，更优选10-70％重量并特别优选30-60％重量，而在产物B中优选的量是1-90％重量，更优选3-85％重量并特别优选5-80％重量，分别地，基于产物A和B所有活性成分的总量。不饱和脂肪酸的优选纯粹植物来源包括晚樱油、亚麻子油、橄榄油和麦胚油而优选的动物来源包括例如鱼油。
可选择地，本发明的两阶段制剂可包含所有已知的植物生物活性物质。用于本发明的植物生物活性物质具体包括类胡萝卜素、植物甾醇、皂草苷、多酚、类黄酮、萜烯、植物雌激素、硫化物、肌醇六磷酸和膳食纤维。上述的植物生物活性物质中，最优选用于本发明的是多酚、类黄酮和生物类黄酮以及膳食纤维。特别优选用于两阶段制剂的是天然来源的生物类黄酮如柑橘水果类黄酮。在优选的实施方案中，出现在两阶段制剂的产物A和/或产物B的植物生物活性物质的量是1-50％重量，更优选1-30％重量且最优选1-20％重量，分别地，基于产物A和B所有活性成分的总量。优选的血管活性和抗氧剂生物类黄酮的天然来源是胡萝卜、花茎甘蓝和柑橘提取物还有绿茶。
本发明的两阶段制剂可选择性地含有所有已知的氨基酸和氨基酸衍生物。优选地，在两阶段制剂中使用氨基酸和/或氨基酸衍生物的混合物，包括氨基酸精氨酸、鸟氨酸、亮氨酸、异亮氨酸，缬氨酸，色氨酸以及氨基酸衍生物牛磺酸和肉碱。进一步优选氨基酸和氨基酸衍生物与维生系B6和辅酶Q10的混合物来促进夜晚阶段的恢复和合成代谢。在优选的实施方案中，氨基酸可以优选单独或以混合物的形式出现在两阶段制剂的产物A和/或产物B中的量是10-95％重量，更优选50-90％重量并最优选80-90％重量，分别地，基于产物A和B所有活性成分的总量。氨基酸及其衍生物优选以纯粹的形式加入。
选择性地，本发明的两阶段制剂可包含所有已知的辅料，添加剂、载体和溶剂。其优选的例子包括牛奶脂肪、氢化、部分氢化和未氢化的大豆脂肪、豆油、胡桃油、甘油、明胶、山梨醇溶液或干品、氧化铁、二氧化钛、专利蓝、喹啉黄、丽春红和水。
可按照本领域熟练技术人员已知的常用方法制备本发明的两阶段制剂，将活性成分与适宜的非毒性、惰性、药学上可接受的固体或液体载体和选择性的常用添加剂、辅料和溶剂混和成盖仑制剂。生产盖仑制剂，如软胶囊的方法是例如叙述于H.Sucker，P.Fuchs，P.Speiser，Pharmazeutische Technologie[药学技术]第二版，1991年，Georg Thieme Verlag，Stuttgart；R.voigt，Lehrbuch der Pharmazentischen Technologie[药学技术手册]，Chemie Verlag 1976；Fahrig和Hofer Die Kapse[胶囊]，Wissenschaftliche Verlagsgesellschaft 1982；Remington′sPharmaceutical Science，1975年第15版，Mack PublishingCompany，Easton，Pennsylvania。
对于本发明的两阶段制剂，所有已知的使用形式如胶囊、片剂、糖衣药丸和溶液等以及所有已知的使用途径都是可能的。但具体地说，优选口服药剂，优选的使用形式是软胶囊、饮用安瓿、小袋包(小安瓿)以及立即可饮的液体。如果，例如，以软胶囊形式提供本发明的两阶段制剂，优选的药剂是这样的：含有适合于白天阶段或运动阶段的适宜营养素的产物A被包含在胶囊A中，胶囊A优选应在早上服用。含有适于夜晚阶段或恢复阶段的适宜营养素的产物B被包含在胶囊B中，胶囊B应优选在晚上服用。分别地，胶囊A和B含有用于一天的白天和夜晚阶段的总剂量。建议每天在早上服用胶囊A在晚上服用胶囊B。可以以药盒的形式提供本发明的两阶段制剂，其中包括例如同样数量的胶囊A和胶囊B。使用的另外形式是饮用安瓿和袋包。但是，也可能将产物A和产物B改装在一个单一使用剂型中来提供，这样产物A和产物B的活性成分在不同的时间释放(即贮存形式)。
通过下列实施例将更详尽地解释本发明。
实施例1
本实施例包含一种在差别时间使用的两阶段制剂，其特别适用于雌性机体，作为膳食补充剂。表1中给出的胶囊A和胶囊B的组合物是按照本领域熟练技术人员通常已知的方法获得的，并按通常方法包含在软胶囊中。另外，制剂中可含有已知的添加剂、辅料和载体、以及溶剂。
表I
胶囊A10mg 胡萝卜提取物200mg 晚樱油100mg 亚麻子油50mg 大豆卵磷酯5mg β胡萝卜素以30％β胡萝卜素悬液的形式30mg 维生素E200mg 维生素C200mg 锌酵母(10mg Zn/g酵母)50mg 镁50mg 得自柑橘水果的类黄酮胶囊B20mg 花茎甘蓝提取物200mg 晚樱油100mg 亚麻子油5mg 维生素E100mg 硅酵母(30mg Si/g酵母)300mg 钙3mg 维生素B13mg 维生素B25mg 维生素B68mg 泛酸10mg 烟酸5μg 维生素B12150μg 叶酸100μg 生物素100mg 锌酵母(10mg Zn/g酵母)50mg 得自柑橘水果的类黄酮。
实施例2
本实施例包含一种在差别时间使用的两阶段制剂，其特别适用于雄性机体，作为膳食补充剂。表II中给出的胶囊A和胶囊B的组合物是按照本领域熟练技术人员通常已知的方法获得的，并按通常方法包含在软胶囊中。另外，制剂中可含有已知的添加剂、辅料和载体、以及溶剂。
表II胶囊A300mg 鱼油(二十碳五烯酸)100mg 亚麻子油100mg 大豆卵磷酯36mg 维生素E200mg 维生素C5mg β胡萝卜素100mg 镁100mg 铬酵母50mg 生物类黄酮胶囊B300mg 橄榄油300mg 麦胚油100mg 镁4.5mg 维生素B15mg 维生素B25mg 维生素B68mg 泛酸10mg 烟酸5μg 维生素B12200mg 锌酵母(10mg Zn/g酵母)100mg 绿茶提取物
实施例3
本实施例包含一种在差别时间使用的两阶段制剂，其特别适用于运动员机体，作为膳食补充剂，表III中给出的胶囊A和袋包B的组合物是按照本领域熟练技术人员通常已知的方法获得的。另外，配方中可含有已知的添加剂、辅料和载体、以及溶剂。
表III胶囊A200mg 镁250mg 亚麻子油250mg 晚樱油36mg 维生素E225mg 维生素C6mg β胡萝卜素4.5mg 维生素B15mg 维生素B25mg 维生素B68mg 泛酸10mg 烟酸5μg 维生素B12200mg 锌酵母(10mg Zn/g酵母)100mg 铬酵母100mg 得自柑橘水果的类黄酮产物B(袋包)
氨基酸和氨基酸衍生物与维生素B6和辅酶Q10的混合物，用来促进夜晚阶段中的恢复和合成代谢并促进脂肪代谢/脂类分解。100mg 锌酵母(10mg Zn/g酵母)100mg 镁200mg 麦胚油50mg 得自柑橘水果的类黄酮2000mg 氨基酸和氨基酸衍生物与维生素B6和辅酶Q10的混合物
Claims (16)
1.在差别时间使用的两阶段制剂，包括用于第一阶段的产物A和用于第二阶段的产物B，其中产物A包含
a)至少一种典型的不饱和脂肪酸和/或
b)至少一种典型的微量元素和矿物质和/或
c)至少一种典型的维生素和/或
d)至少一种典型的植物生物活性物质和/或
e)至少一种氨基酸和/或氨基酸衍生物
而产物B包含：
a)至少一种典型的不饱和脂肪酸和/或
b)至少一种典型的微量元素和矿物质和/或
e)至少一种典型的维生素和/或
d)至少一种典型的植物生物活性物质和/或
e)至少一种典型的氨基酸和/或氨基酸衍生物，
其前提条件是产物A和产物B在它们的数量和/或原料组合物上彼此不同。
2.根据权利要求1的在差别时间使用的两阶段制剂，其包含产物A和产物B，它们彼此独立地包含组分a)、b)和c)。
3.根据权利要求1或2的两阶段制剂，其中产物A和/或产物B还包含大豆卵磷酯。
4.根据权利要求2或3的两阶段制剂，其中产物A和/或产物B还包含至少一种典型的植物生物活性物质。
5.根据权利要求2至4的两阶段制剂，其中产物A和/或产物B还包含氨基酸和/或氨基酸衍生物或氨基酸和/或氨基酸衍生物的混合物。
6.根据权利要求2的两阶段制剂，其包含产物A和产物B，产物A含有的组分a)的量是5-90％重量，组分b)的量是1-80％重量，以及组分c)的量是1-70％重量，而
产物B含有的组分a)的量是1-90％重量，组分b)的量是1-80％重量以及组分c)的量是0.5-50％重量，分别地，基于产物A和B所有活性成分的总量。
7.根据权利要求2的两阶段制剂，其包括产物A和产物B，产物A含有的组分a)的量是30-60％重量，组分b)的量是5-30％重量以及组分c)的量是20-45％重量，而
产物B含有的组分a)的量的是5-80％重量，组分b)的量是3-60％重量以及组分c)的量是1-35％重量，分别地，基于产物A和B的所有活性成分的总量。
8.根据权利要求1或2的两阶段制剂，其中产物A和/或产物B还含有1-40％重量的大豆卵磷脂，分别地，基于产物A和B所有活性成分的总量。
9.根据权利要求1或2的两阶段制剂，其中产物A和/或产物B还含有1-50％重量的至少一种典型的植物生物活性物质，分别地，基于产物A和B所有活性成分的总量。
10.根据权利要求1或2的两阶段制剂，其中产物A和产物B中的不饱和脂肪酸是包含在植物和动物油中的不饱和脂肪酸。
11.根据权利要求1或2的两阶段制剂，其中产物A和产物B的微量元素和矿物质是锌、镁、钙、硅和铬。
12.根据权利要求1或2的两阶段制剂，其中产物A和产物B的维生素是维生素B1、B2、B6、B12、C、E、泛酸、烟酸、叶酸和生物素。
13.根据权利要求1、4或9的两阶段制剂，其中产物A和/或产物B的植物生物活性物质是包含在胡萝卜、花茎甘蓝和柑橘提取物以及绿茶中的生物类黄酮。
14.根据权利要求1或5的两阶段制剂，其中产物A和/或产物B含有精氨酸、鸟氨酸、亮氨酸、异亮氨酸、缬氨酸和色氨酸作为氨基酸和/或牛磺酸和肉碱作为氨基酸衍生物，可以是单一的或者是氨基酸和/或氨基酸衍生物的混合物。
15.根据权利要求1至14的两阶段制剂，用作食品补充剂(膳食补充剂)。
16.根据权利要求1至14的两阶段制剂，用作药品。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP95111978A EP0755633B1 (de) | 1995-07-28 | 1995-07-28 | Zwei-Phasen-Präparat |
| EP95111978.3 | 1995-07-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1193894A true CN1193894A (zh) | 1998-09-23 |
| CN1142724C CN1142724C (zh) | 2004-03-24 |
Family
ID=8219482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB961965622A Expired - Fee Related CN1142724C (zh) | 1995-07-28 | 1996-07-29 | 两阶段制剂 |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US6471969B1 (zh) |
| EP (1) | EP0755633B1 (zh) |
| JP (1) | JP3512198B2 (zh) |
| KR (1) | KR19990035987A (zh) |
| CN (1) | CN1142724C (zh) |
| AT (1) | ATE185949T1 (zh) |
| AU (1) | AU6787896A (zh) |
| BG (1) | BG102279A (zh) |
| BR (1) | BR9609739A (zh) |
| CA (1) | CA2228049C (zh) |
| CZ (1) | CZ298587B6 (zh) |
| DE (1) | DE59507140D1 (zh) |
| DK (1) | DK0755633T3 (zh) |
| EA (1) | EA199800175A1 (zh) |
| EE (1) | EE9800033A (zh) |
| ES (1) | ES2140589T3 (zh) |
| FI (1) | FI980173A (zh) |
| GR (1) | GR3032499T3 (zh) |
| HK (1) | HK1015636A1 (zh) |
| HU (1) | HUP9900522A3 (zh) |
| IL (1) | IL123066A (zh) |
| IS (1) | IS4659A (zh) |
| LT (1) | LT4414B (zh) |
| LV (1) | LV12161B (zh) |
| MX (1) | MX9800796A (zh) |
| NO (1) | NO980358L (zh) |
| PL (1) | PL190474B1 (zh) |
| PT (1) | PT755633E (zh) |
| SI (1) | SI9620105A (zh) |
| SK (1) | SK283208B6 (zh) |
| TR (1) | TR199800150T1 (zh) |
| WO (1) | WO1997004668A2 (zh) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1298659B1 (it) * | 1997-02-27 | 2000-01-12 | Mario Menconi | Procedimento per l'estrazione di una miscela di olii e miscela di olii ottenuti mediante detto procedimento |
| FR2763850B1 (fr) * | 1997-06-02 | 2000-02-18 | Slow Age Creations | Utilisation d'une ubiquinone en association avec un tocopherol et un polyphenol pour le traitement du vieillissement de la peau |
| US6107349A (en) * | 1998-04-16 | 2000-08-22 | Mantynen; Philip R. | Method and composition for treating psoriasis |
| IT1302863B1 (it) * | 1998-11-13 | 2000-10-10 | Sigma Tau Healthscience Spa | Composizione ad attivita' antiossidante e preventiva di alterazionitrombotiche e aterosclerotiche comprendente una carnitina ed un |
| AU5139600A (en) * | 1999-05-27 | 2000-12-18 | Drugtech Corporation | Nutritional formulations |
| US20050037065A1 (en) * | 1999-05-27 | 2005-02-17 | Drugtech Corporation | Nutritional formulations |
| EP1211955A1 (en) * | 1999-08-30 | 2002-06-12 | Ocean Nutrition Canada Ltd. | A nutritional supplement for lowering serum triglyceride and cholesterol levels |
| US6511675B2 (en) * | 2000-06-12 | 2003-01-28 | Access Business Group International, Llc | Composition and method for correcting a dietary phytochemical deficiency |
| EP1319407A1 (en) * | 2001-12-14 | 2003-06-18 | Montoie Import-Export S.A. | Pharmaceutical composition for topical treatment of skin disorders and skin wounds |
| US20030166614A1 (en) * | 2002-03-01 | 2003-09-04 | Harrison Stanley F. | Method for reducing cholesterol and triglycerides |
| TR201907898T4 (tr) * | 2003-01-31 | 2019-06-21 | Dsm Ip Assets Bv | Karotenoidler içeren yeni bileşimler. |
| NZ544699A (en) | 2003-06-17 | 2009-11-27 | Phibrowood Llc | Particulate wood preservative and method for producing same |
| FR2861594B1 (fr) * | 2003-11-03 | 2006-01-20 | Baudry Jacquet | Composition contenant un extrait de the vert et de la vitamine c |
| US20050252408A1 (en) | 2004-05-17 | 2005-11-17 | Richardson H W | Particulate wood preservative and method for producing same |
| US8431165B2 (en) * | 2004-12-13 | 2013-04-30 | Swing Aerobics Licensing, Inc. | Medicament for treatment of cancer and other diseases |
| US8092839B2 (en) * | 2004-12-13 | 2012-01-10 | Swing Aerobics Licensing, Inc. | Medicament for treatment of cancer and other diseases |
| PT2502635E (pt) * | 2008-06-18 | 2013-12-26 | Roberto Fasani | Formulações combinadas para o tratamento |
| WO2011061687A2 (en) | 2009-11-18 | 2011-05-26 | University Of The Free State | Multiple-phase dietary supplement product |
| US9688921B2 (en) | 2013-02-26 | 2017-06-27 | Board Of Regents, The University Of Texas System | Oil quality using a microporous hollow fiber membrane |
| US9643127B2 (en) * | 2010-01-15 | 2017-05-09 | Board Of Regents Of The University Of Texas System | Simultaneous removal of oil and gases from liquid sources using a hollow fiber membrane |
| US9782726B2 (en) | 2010-01-15 | 2017-10-10 | Board Of Regents, The University Of Texas System | Non-dispersive process for oil recovery |
| EP2545788A1 (de) * | 2011-07-13 | 2013-01-16 | Martin Hulliger | Diätisches Mehrkomponentensystem |
| CA2874775C (en) | 2012-06-14 | 2016-09-13 | Board Of Regents, The University Of Texas System | Non-dispersive oil recovery from oil industry liquid sources |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2060601B2 (de) | 1970-09-02 | 1980-05-22 | V. Berthelsen Industrial Commercial Co. A/S, Hellerup (Daenemark) | Nahrungsergänzungsmittel |
| US4070488A (en) * | 1975-11-25 | 1978-01-24 | Davis Rachel D | Nutritive composition |
| FR2394292A1 (fr) * | 1976-03-02 | 1979-01-12 | Krausz Leslie | Chimiotherapeutique nouvelle pour la therapeutique anti-neoplasique, dite " dual therapy " |
| JPS5793913A (en) * | 1980-12-03 | 1982-06-11 | Ajinomoto Co Inc | Enhancing agent for spermous vital power |
| US4466958A (en) * | 1981-03-18 | 1984-08-21 | Morrison L M | Food supplement |
| DE3368377D1 (en) * | 1982-04-16 | 1987-01-29 | Nestle Sa | Lipid composition for oral, enteral or parenteral feeding |
| FR2556593B1 (fr) * | 1983-12-20 | 1987-01-02 | Synthelabo | Composition nutritive contenant de l'acide alpha-cetoisocaproique, de la leucine et des acides amines essentiels et non essentiels |
| BR8506634A (pt) * | 1984-12-20 | 1986-09-09 | Rhone Poulenc Sante | Composicoes para o revestimento de aditivos alimentares destinados aos ruminantes e granulados sob forma de microcapsulas assim revestidos |
| US4753963A (en) * | 1985-09-26 | 1988-06-28 | The Procter & Gamble Company | Nutritional fat suitable for enteral and parenteral products |
| DE3541304A1 (de) * | 1985-11-22 | 1987-05-27 | Scherer Gmbh R P | Orale zubereitungen von knoblauch und verfahren zu ihrer herstellung |
| US4850970A (en) | 1987-03-26 | 1989-07-25 | American Home Products, Corp. | Two part mastitis cannula cap |
| GB8714772D0 (en) * | 1987-06-24 | 1987-07-29 | Efamol Ltd | Essential fatty acid compositions |
| AU620929B2 (en) * | 1988-10-27 | 1992-02-27 | Bar-Ilan University | Method and compositions for treating alzheimer's disease, related dementias and epilepsy |
| US5009640A (en) | 1989-01-19 | 1991-04-23 | The Upjohn Company | Slip cap for cannula use |
| GB8916734D0 (en) * | 1989-07-21 | 1989-09-06 | Efamol Holdings | Pharmaceutical and dietary uses of fatty acids |
| US5073373A (en) * | 1989-09-21 | 1991-12-17 | Osteotech, Inc. | Flowable demineralized bone powder composition and its use in bone repair |
| HU204981B (en) | 1990-10-03 | 1992-03-30 | Tibor Farkas | Method for producing composition supplementing intake of food |
| BE1005479A3 (nl) | 1991-10-31 | 1993-08-03 | Backer Hubert Nv Sa De | Veeartsenijkundig instrument voor de toediening van een geneesmiddel. |
| HUT63751A (en) | 1991-11-01 | 1993-10-28 | Epaker Szoevetkezeti Kft | Method for producing compositions consisting of vegetal lecithin serving for alimentary purpose and/or animal lecithin and materials containing microelements in organic materials and vitamins |
| US5877289A (en) * | 1992-03-05 | 1999-03-02 | The Scripps Research Institute | Tissue factor compositions and ligands for the specific coagulation of vasculature |
| US5518730A (en) * | 1992-06-03 | 1996-05-21 | Fuisz Technologies Ltd. | Biodegradable controlled release flash flow melt-spun delivery system |
| US5514382A (en) * | 1994-10-17 | 1996-05-07 | Sultenfuss; Sherry | Daily vitamin and mineral supplement for women |
-
1995
- 1995-07-28 PT PT95111978T patent/PT755633E/pt unknown
- 1995-07-28 ES ES95111978T patent/ES2140589T3/es not_active Expired - Lifetime
- 1995-07-28 DK DK95111978T patent/DK0755633T3/da active
- 1995-07-28 EP EP95111978A patent/EP0755633B1/de not_active Expired - Lifetime
- 1995-07-28 AT AT95111978T patent/ATE185949T1/de active
- 1995-07-28 DE DE59507140T patent/DE59507140D1/de not_active Expired - Lifetime
-
1996
- 1996-07-29 SK SK123-98A patent/SK283208B6/sk not_active IP Right Cessation
- 1996-07-29 CA CA002228049A patent/CA2228049C/en not_active Expired - Fee Related
- 1996-07-29 SI SI9620105A patent/SI9620105A/sl unknown
- 1996-07-29 CN CNB961965622A patent/CN1142724C/zh not_active Expired - Fee Related
- 1996-07-29 US US08/983,637 patent/US6471969B1/en not_active Expired - Fee Related
- 1996-07-29 EA EA199800175A patent/EA199800175A1/ru unknown
- 1996-07-29 PL PL96324752A patent/PL190474B1/pl not_active IP Right Cessation
- 1996-07-29 HU HU9900522A patent/HUP9900522A3/hu unknown
- 1996-07-29 WO PCT/EP1996/003329 patent/WO1997004668A2/de active IP Right Grant
- 1996-07-29 BR BR9609739-6A patent/BR9609739A/pt not_active Application Discontinuation
- 1996-07-29 CZ CZ0026998A patent/CZ298587B6/cs not_active IP Right Cessation
- 1996-07-29 AU AU67878/96A patent/AU6787896A/en not_active Abandoned
- 1996-07-29 KR KR1019980700649A patent/KR19990035987A/ko not_active Application Discontinuation
- 1996-07-29 EE EE9800033A patent/EE9800033A/xx unknown
- 1996-07-29 MX MX9800796A patent/MX9800796A/es unknown
- 1996-07-29 TR TR1998/00150T patent/TR199800150T1/xx unknown
- 1996-07-29 JP JP50724697A patent/JP3512198B2/ja not_active Expired - Fee Related
- 1996-07-29 IL IL12306696A patent/IL123066A/xx not_active IP Right Cessation
-
1998
- 1998-01-26 IS IS4659A patent/IS4659A/is unknown
- 1998-01-27 FI FI980173A patent/FI980173A/fi unknown
- 1998-01-27 NO NO980358A patent/NO980358L/no not_active Application Discontinuation
- 1998-02-16 LV LVP-98-27A patent/LV12161B/en unknown
- 1998-02-24 BG BG102279A patent/BG102279A/xx unknown
- 1998-02-26 LT LT98-025A patent/LT4414B/lt not_active IP Right Cessation
-
1999
- 1999-03-12 HK HK99101020A patent/HK1015636A1/xx not_active IP Right Cessation
-
2000
- 2000-01-27 GR GR20000400193T patent/GR3032499T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1193894A (zh) | 两阶段制剂 | |
| DE69122025T2 (de) | Nahrhafte Zusammensetzung | |
| CN1117571C (zh) | 改良的钙的饮食增补剂 | |
| US20210220422A1 (en) | Dietary supplement compositions and methods | |
| EP2459013B1 (fr) | Composition nutritive pour femmes allaitant | |
| US20020187204A1 (en) | Diet composition and method of weight management | |
| EP2941261B1 (en) | Synergistic curcuma and cissus compositions for enhancing physical performance and energy levels | |
| WO2006060578A2 (en) | Nutritional supplements containing xanthone extracts | |
| CN101507494A (zh) | 高血脂高血压患者用的特殊膳食用食品 | |
| CN1107666A (zh) | 保健盐 | |
| CN1065411C (zh) | 新型保健营养奶粉及其生产方法 | |
| US20090196862A1 (en) | High dosage Vitamin D | |
| US7416749B2 (en) | Dietary supplement and related method | |
| CN104856000A (zh) | 失眠非全营养配方食品 | |
| KR20080008155A (ko) | 한국인에게 특별히 필요한 비타민, 무기질, 또는 발효시킨천연물을 함유하는 영양제 조성물 | |
| TW202114644A (zh) | 口服產品 | |
| CN1060028C (zh) | 一种主要由谷物瓜菜果组成的健康食品 | |
| US11147761B2 (en) | Topical supplement composition and method of use | |
| DE102014118772B4 (de) | Nahrungsergänzungsmittel in Kapselform enthaltend chinesische Vitalpilze und deren Verwendung | |
| US9808441B2 (en) | Dietary supplement containing alkaline electrolyte buffers | |
| US8889157B1 (en) | Composition for cardiovascular treatment | |
| CN105995674A (zh) | 一种添加盐藻的复合营养素配方 | |
| TWI301404B (zh) | ||
| NZ539775A (en) | Sexual desire and performance enhancement with meal from plants containing protein-bound tryptophan | |
| CN104872640A (zh) | 气虚体质非全营养配方食品 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1015636 Country of ref document: HK |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040324 Termination date: 20100729 |